Posted by Michael Wonder on 11 May 2017
UK patients get early access to AbbVie’s hepatitis regimen
11 May 2017 - AbbVie’s glecaprevir/pibrentasvir has become the first treatment for chronic hepatitis C to be included in the UK’s Early Access to Medicines Scheme.
Glecaprevir/pibrentasvir is a once-daily regimen that combines two distinct antiviral agents - the NS3/4A protease inhibitor glecaprevir (300 mg) and NS5A inhibitor pibrentasvir (120 mg) - dosed once-daily as three oral tablets.
The ribavirin-free treatment is currently being assessed by European regulators as a treatment for all genotypes of the virus after showing high cure rates in clinical trials, but will now become available to certain patients in the UK before a decision is reached.
